Interview with the President and CEO: MabVax Therapeutics Holdings, Inc. (MBVX)

Healthcare >> CEO Interviews >> November 25, 2014

David Hansen is President and CEO of MabVax Therapeutics Holdings, Inc. He is a senior corporate executive with diverse and in-depth experience in the biopharmaceutical business. Mr. Hansen has proven leadership abilities in creating, building, and directing small startup operations and key departments in both large and small biopharmaceutical companies. He has broad therapeutic area expertise, including oncology and immunology. He has had direct responsibility for corporate and commercial development functions, including in and out licensing, product acquisition, strategic planning and new product planning. Most recently, Mr. Hansen was Senior Vice President of Corporate Development at Avanir Pharmaceuticals, a company focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. Prior to that, he was a Founder, President and COO of Xenerex Biosciences, a monoclonal antibody company focusing on development of fully human antibody products. Profile

TWST: Can you give a brief overview of MabVax’s business and your particular approach to treating cancer?

Mr. Hansen: MabVax is a cancer immunotherapy company focused on

Join for free to read a longer excerpt or purchase this article

Interview with the President and CEO: MabVax Therapeutics Holdings, Inc. (MBVX)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the President and CEO: MabVax Therapeutics Holdings, Inc. (MBVX)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS